- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in Cancer
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 4, Pages 795
Publisher
MDPI AG
Online
2021-02-14
DOI
10.3390/cancers13040795
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy
- (2020) Lukas Gorecki et al. PHARMACOLOGY & THERAPEUTICS
- Biomarker-Guided Development of DNA Repair Inhibitors
- (2020) James M. Cleary et al. MOLECULAR CELL
- RBMX is required for activation of ATR on repetitive DNAs to maintain genome stability
- (2020) Tian Zheng et al. CELL DEATH AND DIFFERENTIATION
- Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors
- (2020) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial
- (2020) Panagiotis A Konstantinopoulos et al. LANCET ONCOLOGY
- Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer
- (2020) Jayakumar Nair et al. ONCOGENE
- A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib ( LY2606368 ) in BRCA Wild‐Type , Advanced Triple‐Negative Breast Cancer
- (2020) Margaret E. Gatti‐Mays et al. ONCOLOGIST
- Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice
- (2019) Derek Weycker et al. BMC CANCER
- Differential activity of ATR and WEE1 inhibitors in a highly sensitive subpopulation of DLBCL linked to replication stress
- (2019) Lucy A. Young et al. CANCER RESEARCH
- A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer.
- (2019) Elizabeth Ruth Plummer et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I/II first-in-human trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in subjects with advanced cancer.
- (2019) Udai Banerji et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors.
- (2019) Johann S. De Bono et al. JOURNAL OF CLINICAL ONCOLOGY
- Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor
- (2019) Ronald Knegtel et al. JOURNAL OF MEDICINAL CHEMISTRY
- The Tousled-like kinases regulate genome and epigenome stability: implications in development and disease
- (2019) Sandra Segura-Bayona et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- ATM in DNA repair in cancer
- (2019) Mei Hua Jin et al. PHARMACOLOGY & THERAPEUTICS
- A consensus set of genetic vulnerabilities to ATR inhibition
- (2019) Nicole Hustedt et al. Open Biology
- 450PDA phase I study of ATR inhibitor, AZD6738, as monotherapy in advanced solid tumours (PATRIOT part A, B)
- (2019) M Dillon et al. ANNALS OF ONCOLOGY
- Upregulation of Myt1 Promotes Acquired Resistance of Cancer Cells to Wee1 Inhibition
- (2019) Cody W. Lewis et al. CANCER RESEARCH
- A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer
- (2019) Johanna C. Bendell et al. INVESTIGATIONAL NEW DRUGS
- Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer
- (2019) Kyle C. Cuneo et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?
- (2019) Alice Bradbury et al. PHARMACOLOGY & THERAPEUTICS
- Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors
- (2018) A Italiano et al. ANNALS OF ONCOLOGY
- Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine
- (2018) Siang-Boon Koh et al. CANCER RESEARCH
- Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients
- (2018) Nader Sanai et al. CLINICAL CANCER RESEARCH
- Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma
- (2018) David S. Hong et al. CLINICAL CANCER RESEARCH
- A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma
- (2018) Eduardo Méndez et al. CLINICAL CANCER RESEARCH
- Claspin - checkpoint adaptor and DNA replication factor
- (2018) Veronique A. J. Smits et al. FEBS Journal
- Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors
- (2018) Anish Thomas et al. JOURNAL OF CLINICAL ONCOLOGY
- Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study
- (2018) Jung-Min Lee et al. LANCET ONCOLOGY
- Abstract CT026: Phase I study of AZD6738, an inhibitor of ataxia telangiectasia Rad3-related (ATR), in combination with olaparib or durvalumab in patients (pts) with advanced solid cancers
- (2018) Matthew G. Krebs et al. CANCER RESEARCH
- Mechanisms of PARP inhibitor sensitivity and resistance
- (2018) Alan D. D’Andrea DNA REPAIR
- Mechanisms for stalled replication fork stabilization: new targets for synthetic lethality strategies in cancer treatments
- (2018) Hongwei Liao et al. EMBO REPORTS
- ATR-Mediated Global Fork Slowing and Reversal Assist Fork Traverse and Prevent Chromosomal Breakage at DNA Interstrand Cross-Links
- (2018) Karun Mutreja et al. Cell Reports
- The Impact of p53 Dysfunction in ATR Inhibitor Cytotoxicity and Chemo- and Radiosensitisation
- (2018) Fiona Middleton et al. Cancers
- Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent
- (2018) Kevin M. Foote et al. JOURNAL OF MEDICINAL CHEMISTRY
- State-of-the-art strategies for targeting the DNA damage response in cancer
- (2018) Patrick G. Pilié et al. Nature Reviews Clinical Oncology
- Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs
- (2018) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response
- (2018) Paola Francica et al. Genome Medicine
- Structural Basis of Wee Kinases Functionality and Inactivation by Diverse Small Molecule Inhibitors
- (2017) Jin-Yi Zhu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia
- (2017) Jonathan A. Webster et al. LEUKEMIA RESEARCH
- A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non‐small cell lung cancer
- (2017) Thomas Wehler et al. LUNG CANCER
- Replication Catastrophe: When a Checkpoint Fails because of Exhaustion
- (2017) Luis Toledo et al. MOLECULAR CELL
- Coupling of Homologous Recombination and the Checkpoint by ATR
- (2017) Rémi Buisson et al. MOLECULAR CELL
- ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response
- (2017) Andrew N. Blackford et al. MOLECULAR CELL
- The impact of replication stress on replication dynamics and DNA damage in vertebrate cells
- (2017) Hervé Técher et al. NATURE REVIEWS GENETICS
- The essential kinase ATR: ensuring faithful duplication of a challenging genome
- (2017) Joshua C. Saldivar et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Inhibitors of cyclin-dependent kinases as cancer therapeutics
- (2017) Steven R. Whittaker et al. PHARMACOLOGY & THERAPEUTICS
- PARP inhibitors: Synthetic lethality in the clinic
- (2017) Christopher J. Lord et al. SCIENCE
- ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways
- (2017) Thuc M. Le et al. Nature Communications
- Targeting the ATR-CHK1 Axis in Cancer Therapy
- (2017) Stuart Rundle et al. Cancers
- Functions, Regulation, and Therapeutic Implications of the ATR Checkpoint Pathway
- (2016) Stephanie A. Yazinski et al. Annual Review of Genetics
- Abstract 3717: Defining optimal dose schedules for ATR inhibitors in combination with DNA damaging drugs: Informing clinical studies of VX-970, the first-in-class ATR inhibitor
- (2016) John Pollard et al. CANCER RESEARCH
- Mitotic catastrophe and cancer drug resistance: A link that must to be broken
- (2016) Tatiana V. Denisenko et al. DRUG RESISTANCE UPDATES
- Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers
- (2016) T.A. Yap et al. EUROPEAN JOURNAL OF CANCER
- Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer
- (2016) Giorgio Scagliotti et al. INVESTIGATIONAL NEW DRUGS
- Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer
- (2016) David Hong et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months
- (2016) Suzanne Leijen et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors
- (2016) Suzanne Leijen et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression and prognostic value of the WEE1 kinase in gliomas
- (2016) Darija Music et al. JOURNAL OF NEURO-ONCOLOGY
- A Genome-wide CRISPR Screen Identifies CDC25A as a Determinant of Sensitivity to ATR Inhibitors
- (2016) Sergio Ruiz et al. MOLECULAR CELL
- ETAA1 acts at stalled replication forks to maintain genome integrity
- (2016) Thomas E. Bass et al. NATURE CELL BIOLOGY
- Transcription–replication conflicts: how they occur and how they are resolved
- (2016) Tatiana García-Muse et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors
- (2016) Emiliano Calvo et al. ONCOLOGY
- Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs
- (2016) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Synthetic lethal approaches for assessing combinatorial efficacy of chemotherapeutic drugs
- (2016) Rebecca A. Jackson et al. PHARMACOLOGY & THERAPEUTICS
- Targeting WEE1 Kinase in Cancer
- (2016) Christopher J. Matheson et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors
- (2015) Toshihiko Doi et al. ANTI-CANCER DRUGS
- Preventing replication fork collapse to maintain genome integrity
- (2015) David Cortez DNA REPAIR
- DNA damage control: regulation and functions of checkpoint kinase 1
- (2015) Veronique A. J. Smits et al. FEBS Journal
- Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors
- (2015) Adil I. Daud et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors
- (2015) Khanh Do et al. JOURNAL OF CLINICAL ONCOLOGY
- Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway
- (2015) Marwan Kwok et al. LANCET
- Potential Clinical Uses of CDK Inhibitors: Lessons from Synthetic Lethality Screens
- (2015) Ladislava Vymětalová et al. MEDICINAL RESEARCH REVIEWS
- ATR and a Chk1-Aurora B pathway coordinate postmitotic genome surveillance with cytokinetic abscission
- (2015) Douglas R. Mackay et al. MOLECULAR BIOLOGY OF THE CELL
- Interaction of Chk1 with Treslin Negatively Regulates the Initiation of Chromosomal DNA Replication
- (2015) Cai Guo et al. MOLECULAR CELL
- Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase
- (2015) Rémi Buisson et al. MOLECULAR CELL
- The history and future of targeting cyclin-dependent kinases in cancer therapy
- (2015) Uzma Asghar et al. NATURE REVIEWS DRUG DISCOVERY
- Replication fork reversal in eukaryotes: from dead end to dynamic response
- (2015) Kai J. Neelsen et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- A historical overview of protein kinases and their targeted small molecule inhibitors
- (2015) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Linking the Cell Cycle to Cell Fate Decisions
- (2015) Stephen Dalton TRENDS IN CELL BIOLOGY
- Hitting cancers’ weak spots: vulnerabilities imposed by p53 mutation
- (2015) Evrim Gurpinar et al. TRENDS IN CELL BIOLOGY
- Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma
- (2015) F. Cottini et al. Cancer Discovery
- Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition
- (2015) Fiona K. Middleton et al. Oncotarget
- The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma
- (2015) Mike I. Walton et al. Oncotarget
- Wee1 is required to sustain ATR/Chk1 signaling upon replicative stress
- (2015) Priyanka Saini et al. Oncotarget
- Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors
- (2014) Edward Sausville et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- ATR Pathway Inhibition Is Synthetically Lethal in Cancer Cells with ERCC1 Deficiency
- (2014) K. N. Mohni et al. CANCER RESEARCH
- Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer
- (2014) Tarek M.A. Abdel-Fatah et al. Molecular Oncology
- Development of pharmacodynamic biomarkers for ATR inhibitors
- (2014) Tao Chen et al. Molecular Oncology
- DNA-PKcs is required to maintain stability of Chk1 and Claspin for optimal replication stress response
- (2014) Yu-Fen Lin et al. NUCLEIC ACIDS RESEARCH
- ATR inhibition preferentially targets homologous recombination-deficient tumor cells
- (2014) M Krajewska et al. ONCOGENE
- High expression of wee1 is associated with malignancy in vulvar squamous cell carcinoma patients
- (2013) Gry Irene Magnussen et al. BMC CANCER
- Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours
- (2013) Takashi Seto et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Targeting ATR in DNA damage response and cancer therapeutics
- (2013) Emmanouil Fokas et al. CANCER TREATMENT REVIEWS
- ATR Prohibits Replication Catastrophe by Preventing Global Exhaustion of RPA
- (2013) Luis Ignacio Toledo et al. CELL
- Wee1 kinase as a target for cancer therapy
- (2013) Khanh Do et al. CELL CYCLE
- Inhibition of Wee1 Sensitizes Cancer Cells to Antimetabolite Chemotherapeutics In Vitro and In Vivo, Independent of p53 Functionality
- (2013) A. A. Van Linden et al. MOLECULAR CANCER THERAPEUTICS
- Causes and consequences of replication stress
- (2013) Michelle K. Zeman et al. NATURE CELL BIOLOGY
- Targeting nuclear kinases in cancer: Development of cell cycle kinase inhibitors
- (2013) Todd M. Pitts et al. PHARMACOLOGY & THERAPEUTICS
- WEE1 tyrosine kinase, a novel epigenetic modifier
- (2013) Kiran Mahajan et al. TRENDS IN GENETICS
- DNA Damage Sensing by the ATM and ATR Kinases
- (2013) A. Marechal et al. Cold Spring Harbor Perspectives in Biology
- Targeting radiation-resistant hypoxic tumour cells through ATR inhibition
- (2012) I M Pires et al. BRITISH JOURNAL OF CANCER
- Cyclin F-Mediated Degradation of Ribonucleotide Reductase M2 Controls Genome Integrity and DNA Repair
- (2012) Vincenzo D'Angiolella et al. CELL
- Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias
- (2012) J. E. Karp et al. CLINICAL CANCER RESEARCH
- Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer
- (2012) Glen J. Weiss et al. INVESTIGATIONAL NEW DRUGS
- Thresholds of replication stress signaling in cancer development and treatment
- (2012) Jiri Bartek et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- H2B Tyr37 phosphorylation suppresses expression of replication-dependent core histone genes
- (2012) Kiran Mahajan et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- The CDK1 inhibitory kinase MYT1 in DNA damage checkpoint recovery
- (2012) J P H Chow et al. ONCOGENE
- Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
- (2012) Marieke Aarts et al. Cancer Discovery
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- WEE1 Kinase Targeting Combined with DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe
- (2011) P. C. De Witt Hamer et al. CLINICAL CANCER RESEARCH
- Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease
- (2011) Raquel Domínguez-Kelly et al. JOURNAL OF CELL BIOLOGY
- Targeting ATR and Chk1 kinases for cancer treatment: A new model for new (and old) drugs
- (2011) Luis I. Toledo et al. Molecular Oncology
- A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations
- (2011) Luis I Toledo et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Anticancer therapy with checkpoint inhibitors: what, where and when?
- (2011) Michelle D. Garrett et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Novel insights into maintaining genomic integrity: Wee1 regulating Mus81/Eme1
- (2011) Yusé Martín et al. Cell Division
- MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil
- (2010) Hiroshi Hirai et al. CANCER BIOLOGY & THERAPY
- 201 Evaluation of the antitumor activity of pemetrexed in combination with the Chk1 inhibitor LY2603618
- (2010) M. Marshall et al. EJC SUPPLEMENTS
- Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents
- (2010) S Zenvirt et al. ONCOGENE
- Chk1 promotes replication fork progression by controlling replication initiation
- (2010) E. Petermann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Common mechanisms of PIKK regulation
- (2009) Courtney A. Lovejoy et al. DNA REPAIR
- Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents
- (2009) H. Hirai et al. MOLECULAR CANCER THERAPEUTICS
- A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging
- (2009) Matilde Murga et al. NATURE GENETICS
- The DNA-damage effector checkpoint kinase 1 is essential for chromosome segregation and cytokinesis
- (2009) S. Peddibhotla et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Chk1 Suppresses a Caspase-2 Apoptotic Response to DNA Damage that Bypasses p53, Bcl-2, and Caspase-3
- (2008) Samuel Sidi et al. CELL
- Chk1 Is a Histone H3 Threonine 11 Kinase that Regulates DNA Damage-Induced Transcriptional Repression
- (2008) Midori Shimada et al. CELL
- Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery
- (2008) Libor Macůrek et al. NATURE
- ATR: an essential regulator of genome integrity
- (2008) Karlene A. Cimprich et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage
- (2008) E M Bahassi et al. ONCOGENE
- Bora and the Kinase Aurora A Cooperatively Activate the Kinase Plk1 and Control Mitotic Entry
- (2008) A. Seki et al. SCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search